Methodological proposal to explore and design future health innovation policies and opportunities for Responsible Research and Innovation (RRI)

Responsible Research and Innovation (RRI) seeks to align the research results with the needs of society to respond to current and future problems, also encompassing financial instruments, innovative public policies, and the distribution of resources. These policies should prioritize research in those areas with the greatest impact on society, and particularly in health research, this impact should be focused on responding to clinical problems of the population rather than economic impact. A methodology is proposed that uses information from open sources to identify discrepancies between the results of the most translational research of a region and its health needs, in order to provide useful information for the formulation of innovation policies.


Introduction
Responsible Research and Innovation (RRI) was promoted by the European Commission in November 2014 through the Rome Declaration on RRI, calling on member states and their organizations and institutions to focus and prioritize RRI, declaring it essential for sustainable innovation and highlighting the responsibility of scientific achievement to be able to meet the needs and expectations of society. The statement also included the need to search for methodologies to design future innovation policies 1 .
Since the middle of the last century, patents have been used as a source of information for evaluating science and technology activities, and its use has increased as data has become more accessible electronically 2 .
However, such information is imperfect (for example, not all innovations or inventions are patented), and its limitations should be considered when using it to formulate R&D&I policies, so it should preferably be combined with other indicators 3 .
In the biomedical field, the clinical application of most technologies requires substantial investment in research and development, so the use of industrial property rights, including patents, usually accompanies the development of these technologies from the earliest stages to reduce the risk of not maximizing the investment. This makes patents in this field especially useful for the identification of new technologies and technological changes, the analysis of technological trends, the analysis and monitoring of competitors, and the support for decision making in the planning and management of R&D&I 4,5 .
The information contained in clinical trials is frequently used for competitive intelligence analysis in the pharmaceutical field, together with market and patent information 6 , and it is also used for reviews. Since In this work we describe a methodology for obtaining information that will allow the definition of future health innovation policies, for the identification of research opportunities and prioritization of R&D&I funding through the prioritization of the projects that best suit the biomedical technologies of interest detected.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The results obtained are shown in Table 1 and have been represented as percentages of the total analyzed in Figure 1. The data from the study can be consulted at (Reserved DOI: 10.17632/m3gtm59vfg.1). Figure 1 shows that circulatory diseases are the main cause of mortality and morbidity in Spain; however, the number of patents and clinical trials, indicators of investment in this area, is not equivalent. In neoplasms, the second leading cause of death, a correlation is observed. In diseases of the digestive system, genitourinary system and respiratory system, there is a deviation between morbidity and the clinical trials registered. With respect to skin, endocrine and nervous system diseases, a greater inversion is observed, that is not in accordance with the mortality and morbidity data.

Discussion
The same methodology could be applied at a more specific level, for example, to determine the R&D&I situation in specific diseases that are particularly prevalent in a region.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted May 12, 2021. ; https://doi.org/10.1101/2021.05.10.21256984 doi: medRxiv preprint Specific developments and mechanisms have been generated to include in the research and innovation process the social utility of science and its potential impacts, enabling greater assurance of translational research. Currently, RRI is a topic that involves researchers, companies, scientific institutions, and research funding agencies. It is therefore proposed to use the term collective responsibility 10 to define this concept and to implement the positive impacts of research and innovation.
The collection, correlation and processing of publicly accessible data such as patents and clinical trials can be used to obtain useful information 11,12 , particularly in the formulation of regional innovation policies 13,14 .
By adding ICD statistics, it is possible to identify technological fields where, for reasons of public health, it may be interesting to prioritize research funding from the public sector, so that public research and innovation have an impact on clinical care, fostering a culture of RRI in the scientific community and facilitating the transfer of scientific achievements to society. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 12, 2021. ; . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted May 12, 2021. ; https://doi.org/10.1101/2021.05.10.21256984 doi: medRxiv preprint